Search Results - "Stargardt, T"

Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain by Marrett, E, Stargardt, T, Mavros, P, Alexander, C.M

“…To examine the association between medication side-effects (SEs) and patient-reported outcomes (PROs) among patients with type 2 diabetes treated with oral…”
Get full text

Health economic evaluation based on administrative data from German health insurance by Schreyögg, J, Stargardt, T

“…Although the quality of administrative data of German health insurance is relatively good, administrative data are rarely used for the purpose of health…”
Get full text

Forecasting Outpatient Pharmaceutical Expenditure for Cancer Treatment in Germany by Schoch, G.G, Blank, S, Tamminga, M, Steimle, T, Stargardt, T

Get full text

PMH16 Analysis of the Economic Burden and Cost Structure of Schizophrenia in Germany Using Observational Sickness Fund Data by Frey, S, Linder, R, Stargardt, T

Get full text

AD1 Compliance Measurement Using Administrative Data From German Sickness Funds by Frey, S, Stargardt, T

Get full text

Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund by Weinbrenner, S, Assion, H-J, Stargardt, T, Busse, R, Juckel, G, Gericke, C A

“…The aim of this study was to investigate routine administrative data from a major German health insurance fund, Techniker Krankenkasse, which covers 5.4…”
Get more information

Defining the "Health Benefit Basket" in Nine European Countries: Evidence from the European Union Health BASKET Project by Schreyögg, J., Stargardt, T., Velasco-Garrido, M., Busse, R.

“…This article identifies and analyses a framework for "health baskets," the taxonomy of benefit catalogues for curative services, and the criteria for the in-…”
Get full text

Authorization and reimbursement of orphan drugs in an international comparison by Roll, K, Stargardt, T, Schreyögg, J

“…This paper analyses schemes to promote the authorisation of and reimbursement for orphan drugs. 8 countries - Australia, Canada, Germany, Great Britain,…”
Get more information

PMH36 Cost-Effectiveness of Depot Flupentixol Versus Long-Acting Risperidone – A Markov Model Parameterized Using Administrative Data by Frey, S, Stargardt, T, Linder, R, Juckel, G

Get full text

PCN55 The Cost of Rare Diseases: The Example of Chronic Lymphocytic Leukemia by Blankart, C.R, Koch, T, Linder, R, Verheyen, F, Schreyögg, J, Stargardt, T

Get full text

Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus by Stargardt, T, Yin, D.D, Alexander, C.M

“…This study investigates the treatment choice between, and the effectiveness of, adding sulphonylurea or glitazone to ongoing metformin therapy for patients…”
Get full text

Reforms in the Greek pharmaceutical market during the financial crisis by Vandoros, Sotiris, Stargardt, Tom

“…Abstract Introduction Following the financial crisis of 2008, Greece has been facing severe fiscal problems associated with high public debt and deficit. Given…”
Get full text

Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting by Birkner, Benjamin, Rech, Jürgen, Edelmann, Edmund, Verheyen, Frank, Schett, Georg, Stargardt, Tom

“…Abstract Objective We aim to provide real-world evidence on the effectiveness of patient-individual tapering of DMARDs for patients with RA in daily clinical…”
Get full text

N02 Inflammatory bowel disease patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomized controlled trial in Germany (IBDBIO-ASSIST study) - The IBD nurses perspective by Hartmann, P, Zemke, J, Plachta-Danielzik, S, Steiner, I M, Pohlschneider, D, Urzica, E, Tappe, U, Schreiber, S, Steinkat, N, Langbrandtner, J, Hüppe, A, Stargardt, T, Bokemeyer, B

Get full text

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches by Buck, Andreas K, Herrmann, Ken, Stargardt, Tom, Dechow, Tobias, Krause, Bernd Joachim, Schreyogg, Jonas

“…PET and PET/CT have changed the diagnostic algorithm in oncology. Health care systems worldwide have recently approved reimbursement for PET and PET/CT for…”
Get full text

Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis by Birkner, Benjamin, Rech, Jürgen, Edelmann, Edmund, Verheyen, Frank, Schett, Georg, Stargardt, Tom

“…Objective To provide real-world evidence on patient-individual tapering patterns of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA)…”
Get full text

Battling the infodemics: health communication effectiveness during COVID-19 by Sabat, I, Varghese, N E, Neuman-Böhme, S, Barros, P P, Brouwer, W, van Exel, J, Schreyögg, J, Stargardt, T

“…Abstract The coronavirus disease (COVID-19) outbreak in many parts of the world has posed serious concerns to the public health. During this period of crisis,…”
Get full text

Countering COVID-19: A European survey on acceptability of and commitment to preventive measures by Sabat, I, Elsem Varghese, N, Neuman-Böhme, S, Pita Barros, P, Brouwer, W, van Exel, J, Schreyögg, J, Stargardt, T

“…Abstract To understand the public sentiment toward the measures used by policymakers for COVID-19 containment, a survey among representative samples of the…”
Get full text

PCN43 - Forecasting Outpatient Pharmaceutical Expenditure for Cancer Treatment in Germany by Schoch, G.G., Blank, S., Tamminga, M., Steimle, T., Stargardt, T.

Get full text

Gesundheitsökonomische Evaluation auf Grundlage von GKV-Routinedaten by Schreyögg, J., Stargardt, T.

“…Zusammenfassung Obwohl die Qualität der GKV-Routinedaten in Deutschland vergleichsweise gut ist, kommen sie im Rahmen gesundheitsökonomischer Evaluationen nur…”
Get full text